← Back to Search

Cancer Vaccine

Pneumovax 23- pneumococcal polysaccharide for Type 1 Diabetes

Phase 4
Waitlist Available
Led By Ana Creo, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Children ages 3-18 years old.
Clinical diagnosis of Type 1 diabetes.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post vaccination
Awards & highlights

Study Summary

This trial looks at whether kids with type 1 diabetes have a strong enough immune response to the PPSV23 vaccination, and what might affect that response.

Eligible Conditions
  • Type 1 Diabetes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Immunoglobulin G (IgG) Antibodies

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pneumovax 23Experimental Treatment2 Interventions
Type 1 Diabetes subjects will receive Pneumovax 23-pneumococcal polysaccharide (PPSV23)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood draw
2021
Completed Phase 4
~6290
Pneumovax 23- pneumococcal polysaccharide
2021
Completed Phase 4
~30

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,176 Previous Clinical Trials
3,758,022 Total Patients Enrolled
Ana Creo, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
23 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does eligibility for this clinical trial include individuals of all ages, or is there an upper age limit?

"This study only seeks participants that fall between the ages of 3 and 18. Out of all available clinical trials, 226 are dedicated to those under eighteen while 934 are tailored towards seniors over 65 years old."

Answered by AI

To what degree is Pneumovax 23- pneumococcal polysaccharide safe for human consumption?

"Pneumovax 23- pneumococcal polysaccharide has been officially approved, so it is accorded a score of 3 in terms of safety."

Answered by AI

How many individuals are partaking in this research program?

"Affirmative. Information hosted on the clinicaltrials.gov website indicates that this trial is actively enrolling participants, with an initial posting date of 4/30/2021 and most recent update occurring 11/9/2022. The research team requires 100 volunteers across a single site to complete the study."

Answered by AI

Do I meet the prerequisites to take part in this clinical evaluation?

"To qualify for the trial, participants must suffer from type 1 diabetes mellitus and be 3 to 18 years old. The study aims to recruit a total of 100 individuals."

Answered by AI

Is this medical research currently enrolling participants?

"According to clinicaltrials.gov, this trial is still searching for participants. The initial post was made on April 30th 2021 and the most recent revision occurred on November 9th 2022."

Answered by AI
~8 spots leftby Mar 2025